1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Asaf Danziger

No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700


Evercore ISI Is Pounding the Table on Rivian (RIVN) Stock With Outperform Rating
Nov 28, 2023 16:35pm

Rivian (NASDAQ: RIVN ) stock is a hot topic on Tuesday after Evercore ISI weighed in on the electric vehicle (EV) company’s shares. The big news here is Evercore ISI’s analysts reiterating their “outperform” rating for RIVN stock. The firm’s analysts said the following about Rivian in a note to clients obtained by CNBC . “Ahead of our visit, after Q3, we have updated our model with the latest in management’s comments around the crucial ’24 gross margin bridge which will see substantial architectural/technology improvements during the mid-year shutdown/line transition.” Investors will note that Evercore ISI is remaining bullish on RIVN stock after upgrading the shares to “outperform” back in October . That came with a price target of $35 per share. That’s still a higher target than the current analysts’ consensus estimate of $28.95 per share. RIVN Stock Rises on Lease News To go along with the reiterated rating from Evercore ISI, Rivian has announced an expanded leasing program for its R1T electric pickup truck.

Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts
Nov 28, 2023 15:51pm

Novocure (NASDAQ: NVCR ) layoffs are in the news after the company announced that it will be cutting 13% of its workers in a restructuring effort. Those layoffs will see the oncology company reducing its headcount by 200 workers. Doing so will drop its residual operating expenses by about $60 million. Novocure expects to suffer a roughly $7 million charge in the fourth quarter of 2023 as a result of these job cuts. Asaf Danziger, CEO of Novocure, said the following about the layoffs. “The initiatives announced today prioritize growth and maintain financial health and flexibility as we position our company for future profitability. These decisions were difficult, yet essential. With a more focused organization, we are confident that these initiatives will bolster Novocure’s position, enabling us to unlock our long-term potential and fulfill our mission.” The Novocure layoffs come alongside changes to its portfolio prioritization. This will see the company focus on clinical trials TRIDENT, KEYNOTE D58 and LUNAR-2.

Novocure to eliminate 13% of workforce in restructuring effort
Nov 28, 2023 12:51pm

Novocure announces strategic restructuring plan and layoffs, aiming to reduce expenses.

Source:Seeking Alpha
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Nov 28, 2023 12:30pm

Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation. The plan includes an expected reduction in residual operating expenses of approximately $60 million, enabling the Company to fund future growth priorities without an associated increase in expected forward operating cash burn.

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
Nov 21, 2023 12:00pm

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.

Source:Business Wire
NovoCure: Significant Upside Even Without A Breakthrough
Nov 17, 2023 00:54am

NovoCure (NVCR) is pursuing growth through expanding markets served, clinical trials for different cancers, and investments in marketing and SG&A. Read more here.

Source:Seeking Alpha
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
Nov 10, 2023 13:00pm

Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in Vancouver, Canada.

NovoCure (NASDAQ:NVCR) Releases Earnings Results, Beats Expectations By $0.05 EPS
Oct 29, 2023 13:04pm

NovoCure (NASDAQ:NVCR – Get Free Report) issued its earnings results on Thursday. The medical equipment provider reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.05, Briefing.com reports. NovoCure had a negative net margin of 39.14% and a negative return on equity of 45.91%. The business had revenue of $127.30 million […]

Source:The AM Reporter
Why Novocure Stock Was Sick Today
Oct 26, 2023 20:35pm

Investors weren''t particularly pleased with the company''s third-quarter performance.

Source:The Motley Fool
NovoCure Limited 2023 Q3 - Results - Earnings Call Presentation
Oct 26, 2023 15:17pm

The following slide deck was published by NovoCure Limited in conjunction with their 2023 Q3 earnings call.

Source:Seeking Alpha